Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Yu Sunakawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0163-7543; OpenAlex author ID A5013994958. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 9

  1. Diagnostic performance of droplet digital PCR for KRAS mutation analysis in pancreatic cancer cytology specimens. Last author DOI 10.1007/s00535-026-02447-9↗
  2. Orbital Metastasis of Pancreatic Cancer Not Detected on MRI at the Time of Clinical Presentation. First author DOI 10.21873/cdp.10583↗
  3. A Case of Pancreatic Ductal Adenocarcinoma in PRSS1-Associated Hereditary Pancreatitis in the Absence of High-Grade PanIN: Suggestive of Chromothripsis-Like Tu… Co-author DOI 10.1111/pin.70055↗
  4. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  5. Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. Co-author DOI 10.3389/frhs.2024.1275496↗
  6. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. First author DOI 10.1038/s41416-023-02189-y↗
  7. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2208470↗
  8. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer. First author DOI 10.1016/j.critrevonc.2021.103465↗
  9. Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX. First author DOI 10.18632/oncotarget.12007↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kumiko Umemoto · 4 shared papers, 2021–2026 · strength 0.83
  2. Takashi Ogura · 1 shared paper, 2026 · strength 0.63
  3. Kazunari Nakahara · 2 shared papers, 2025–2026 · strength 0.48
  4. Tomoko Norose · 2 shared papers, 2025–2026 · strength 0.48
  5. Junki Koike · 2 shared papers, 2025–2026 · strength 0.48
  6. Hiroyuki Takeda · 2 shared papers, 2024–2026 · strength 0.42
  7. Makoto Ueno · 2 shared papers, 2023–2024 · strength 0.32
  8. Shinjiro Kobayashi · 1 shared paper, 2025 · strength 0.25
  9. Yosuke Igarashi · 1 shared paper, 2026 · strength 0.23
  10. Yuriko Sasahara · 1 shared paper, 2024 · strength 0.19
  11. Takashi Yoshioka · 1 shared paper, 2024 · strength 0.19
  12. Yuki Takumoto · 1 shared paper, 2024 · strength 0.19
  13. Hiroto Narimatsu · 1 shared paper, 2024 · strength 0.19
  14. Manabu Akazawa · 1 shared paper, 2024 · strength 0.19
  15. Laëtitia Dahan · 1 shared paper, 2023 · strength 0.14
  16. John H. Strickler · 1 shared paper, 2023 · strength 0.14
  17. Charlotte Lemech · 1 shared paper, 2023 · strength 0.14
  18. David Lawrence Bajor · 1 shared paper, 2023 · strength 0.14
  19. Antoine Hollebecque · 1 shared paper, 2023 · strength 0.14
  20. Andrew L. Coveler · 1 shared paper, 2023 · strength 0.14
  21. Thomas J. George · 1 shared paper, 2023 · strength 0.14
  22. Rona D. Yaeger · 1 shared paper, 2023 · strength 0.14
  23. David S. Hong · 1 shared paper, 2023 · strength 0.14
  24. Ignacio Garrido‐Laguna · 1 shared paper, 2023 · strength 0.14
  25. Kentaro Sudo · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.